CJC-1295 and ipamorelin are combined because they act on two different receptors in the pituitary gland. CJC-1295 stimulates the growth hormone releasing hormone receptor, ipamorelin the ghrelin receptor. When both pathways fire at once, the growth hormone pulse is markedly larger than from either molecule alone.
There are, however, no randomised human trials of this pair. The wider context of both groups is covered in the pillar article on how peptides stimulate growth hormone release.
What does the synergy of CJC-1295 and ipamorelin rest on?
The two peptides trigger different pathways inside the cell. Stimulating the GHRH receptor raises cyclic AMP and opens voltage-gated calcium channels. Stimulating the ghrelin receptor works mainly through protein kinase C and a separate calcium-dependent pathway. When both mechanisms fire together, the resulting growth hormone pulse is considerably stronger than the sum of each on its own.
Hence the rule repeated in descriptions of this pair: the GHRH analogue tells the pituitary how much hormone to release, and the GHRP opens the way for that release. Neither delivers growth hormone from outside. Both act on the cell that produces it.
What is known about CJC-1295 from human studies?
CJC-1295 has a published study in healthy adults. Work by Teichman and co-authors, published in 2006 in the Journal of Clinical Endocrinology and Metabolism, covered people aged 21 to 61 who received escalating single doses or repeated doses weekly or every two weeks.
Three numbers from that study are worth knowing. The half-life of the molecule was 5.8 to 8.1 days. Growth hormone levels rose 2 to 10 times and stayed elevated for more than six days. Levels of insulin-like growth factor IGF-1 rose 1.5 to 3 times and remained elevated for 9 to 11 days.
These data concern the version with the action-extending technology, marked as CJC-1295 with DAC. The version without DAC acts briefly.
What is known about ipamorelin alone?
Ipamorelin was first described in 1998 in the European Journal of Endocrinology. The authors, Raun and colleagues, showed that this pentapeptide releases growth hormone with a potency comparable to GHRP-6.
The most important finding of that work concerns something else. Unlike GHRP-2 and GHRP-6, ipamorelin did not raise ACTH or cortisol above the levels seen after GHRH alone. That is where the label “clean” or “selective” comes from. The full profile of the molecule is set out in the article on why ipamorelin is called a clean GHRP.
Has the synergy of this pair been proven in humans?
Not for this particular pair. As of April 2026, no randomised human trials had been published for the combination of CJC-1295 with ipamorelin. Mechanistic support comes from studies of related pairings of a GHRH analogue with a GHRP, in which adding a GHRP to GHRH raised peak growth hormone several times over. That does not transfer directly to the safety or efficacy of the CJC-1295 and ipamorelin pair itself.
The difference between those two statements matters and is often blurred. What has been studied is the mechanism, the way two receptors work together. What has not been studied is the end result in a person: change in body composition, strength, recovery, or safety after many months. A description that promises the second on the basis of the first runs ahead of the data.
How is this pair dosed?
There is no established dosing protocol supported by trials, which is why this article does not end with a dose table. The choice of dose and schedule is a decision for a doctor after assessing indications and contraindications, not something to settle from shop descriptions.
For the same reason you will not find administration times or cycle lengths here. Figures circulating on forums do not come from clinical trials but from user reports, and those say nothing about safety.
What is the legal status of CJC-1295 and ipamorelin?
As of April 2026 both peptides are in category 2 of the FDA 503A list and cannot legally be prepared in compounding pharmacies until the agency completes its review. Both also appear on the World Anti-Doping Agency list in category S2, prohibited at all times, in and out of competition.
For an athlete subject to anti-doping control this means one thing: reaching for either is a rule violation, regardless of how the seller described the product.
What is in the shop from this pair?
In our shop both peptides appear only as research material. Separately you can buy CJC-1295 5 mg and ipamorelin 10 mg. The extended-action version is offered as CJC-1295 with DAC 5 mg.
A ready-made combination of both molecules in one vial is Ipamorelin & CJC-1295 Combo 10 mg. The whole group is gathered in the growth hormone peptides category. The cart and the checkout are in English and prices are shown in Polish zloty.
Frequently asked questions
Why is CJC-1295 combined with ipamorelin?
Because they act on two different pituitary receptors: CJC-1295 on the GHRH receptor, ipamorelin on the ghrelin receptor. Stimulating both at once gives a stronger growth hormone pulse.
Are there human studies of this pair?
There are no randomised trials of the CJC-1295 and ipamorelin combination itself. The data come from studies of related pairings of a GHRH analogue with a GHRP.
How long does CJC-1295 act?
In a study in healthy adults from 2006 the half-life was 5.8 to 8.1 days. Growth hormone was elevated for more than six days and IGF-1 for 9 to 11 days.
Why is ipamorelin regarded as milder than GHRP-6?
In a 1998 study it released growth hormone with a potency comparable to GHRP-6 but did not raise ACTH or cortisol above the levels seen after GHRH alone.
How should CJC-1295 with ipamorelin be dosed?
There is no protocol supported by trials. Dosing of peptide drugs is a decision for a doctor after assessing indications and contraindications.
Is this pair legal?
Both peptides are in category 2 of the FDA 503A list and on the World Anti-Doping Agency list in category S2. Neither is a registered medicine.
Where this information comes from
The intracellular pathways of both receptors, the amplification of the growth hormone pulse, the absence of randomised trials for this pair as of April 2026 and the status of both peptides on the FDA 503A list come from material published by Superpower on 18 April 2026, updated to 2 August 2026. That page was checked on 31 August 2026.
The human data on CJC-1295 come from Teichman SL and co-authors, “Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults”, Journal of Clinical Endocrinology and Metabolism 2006, PMID 16352683. The profile of ipamorelin comes from Raun K and co-authors, “Ipamorelin, the first selective growth hormone secretagogue”, European Journal of Endocrinology 1998, PMID 9849822. Both abstracts were read through Europe PMC on 7 September 2026.